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Abstract
Background: About 5% of western populations are afflicted by autoimmune diseases many of which are
affected by sex hormones. Autoimmune diseases are complex and involve many genes. Identifying these
disease-associated genes contributes to development of more effective therapies. Also, association studies
frequently imply genomic regions that contain disease-associated genes but fall short of pinpointing these
genes. The identification of disease-associated genes has always been challenging and to date there is no
universal and effective method developed.
Results:  We have developed a method to prioritize disease-associated genes for diseases affected
strongly by sex hormones. Our method uses various types of information available for the genes, but no
information that directly links genes with the disease. It generates a score for each of the considered genes
and ranks genes based on that score. We illustrate our method on early-onset myasthenia gravis (MG)
using genes potentially controlled by estrogen and localized in a genomic segment (which contains the
MHC and surrounding region) strongly associated with MG. Based on the considered genomic segment
283 genes are ranked for their relevance to MG and responsiveness to estrogen. The top three ranked
genes, HLA-G, TAP2 and HLA-DRB1, are implicated in autoimmune diseases, while TAP2 is associated
with SNPs characteristic for MG. Within the top 35 prioritized genes our method identifies 90% of the 10
already known MG-associated genes from the considered region without using any information that
directly links genes to MG. Among the top eight genes we identified HLA-G and TUBB as new candidates.
We show that our ab-initio approach outperforms the other methods for prioritizing disease-associated
genes.
Conclusion: We have developed a method to prioritize disease-associated genes under the potential
control of sex hormones. We demonstrate the success of this method by prioritizing the genes localized
in the MHC and surrounding region and evaluating the role of these genes as potential candidates for
estrogen control as well as MG. We show that our method outperforms the other methods. The method
has a potential to be adapted to prioritize genes relevant to other diseases.
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Background
Collectively, ~5% of western populations are afflicted by
autoimmune diseases, such as type I diabetes, rheumatoid
arthritis and multiple sclerosis (MS) [1,2]. Hormonal
influences are strongly implicated by their frequent
female bias and onset between puberty and the meno-
pause [3]. The strongest known susceptibility loci mostly
reside in the major histocompatibility complex (MHC)
[4], as in MS, where the very tightly linked HLA-DR51 and
-DR15 predispose significantly [5]; there may also be an
independent association with the loosely linked HLA-A3
[6] or nearby loci (A simple map of extended MHC region
is provided in Figure 1). Most workers agree that mainly T
cells specific for myelin antigens mediate the damage,
though autoantibodies may also contribute in some
patients.
There are additional clues to pathogenesis in the particu-
larly well defined subgroup of European patients with
early-onset myasthenia gravis MG (EOMG). Their muscle
weakness is clearly mediated by highly mutated, high
affinity, complement-activating, IgG antibodies to the
acetylcholine receptor (AChR). EOMG patients show a 3:1
female bias and onset almost always after puberty but
before age 45 years. They subside to below control fre-
quencies in patients with onset after age 50 [7]. The HLA-
associations with -DR3 and especially -B8 in the class I
region extend at least a further 1 Mbp telomerically
towards HLA-E – the 'target region' for EOMG – though
they decline nearer to HLA-A, and centromerically
towards -DR [7]. Some reports map the predisposing
'MYAS-1 gene' to the class III region near TNF [8]. In the
UK, these associations appeared even stronger in the
females than the males [7].
In the normal thymus, some epithelial cells express AChR
subunits and HLA-DR; presumably, their proper function
is to induce self-tolerance in newly developing T cells [9].
However, in EOMG, these cells appear 'hyperplastic' and
may be responsible for autoimmunizing helper T cells
[10,11], and for provoking the characteristic lymph node-
type infiltrates, eg by releasing chemokines [12,13]. Rare
myoid cells express the complete AChR, and are impli-
cated in formation of the characteristic germinal centers
(GC) nearby, many of which are AChR-specific [14]. It is
probably in these sites of Ig class switching and somatic
hypermutation [15] that the primordial autoantibodies
evolve and diversify so that, like those in most patients'
sera, they recognize the native conformation of the intact
receptor. This evolution can apparently stop at intermedi-
ate stages with autoantibodies exclusively of low affinity
that are hard to detect in standard assays ('seronegative')
but are nonetheless pathogenic [16] and associate with
mild thymic hyperplasia [17].
Evidently, there are many stages at which susceptibility
genes could contribute, including those mentioned
above. Others may include the 'danger signals' and/or
cytokines [18] that favor initial T cell autoimmunization
rather than tolerance, the strength of the primordial anti-
body response and of the consequent complement attack
on myoid and epithelial cells [17,19] which may depend
on complement receptors and regulators as well as acti-
vated components, and may also amplify the infiltration.
Furthermore, other genes may influence the terminal
effector mechanisms at the motor endplates in muscle, or
protect against them, for example, via complement regu-
lators or rapsyn over-expression [20], though there are no
clinical hints of hormone involvement at this stage.
Hormonal influences also seem likely in systemic lupus
erythematosus (SLE) and Graves' disease, which again
show female biases and onset in young adults. They may
be especially relevant to MG as both are mediated by
autoantibodies and both show associations with HLA-
DR3 [21,22]; complement is also heavily involved in SLE.
Indeed, in animal models of SLE, gonadectomy clearly
has major effects on susceptibility/resistance [3,23]. In
humans, SLE is well known to 'flare' during pregnancy,
when estrogens and progesterone levels are highest [3]
and there is a bias in favor of Th2 responses. There may
also be exacerbations in MG during pregnancy or men-
struation [24,25]. In addition, reduced testosterone could
also be important in auto-immune diseases [26].
A simplified map of extended MHC Figure 1
A simplified map of extended MHC.
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In general, steroid hormones are recognized initially by
intracellular receptors that then bind to Hormone-
Response Elements on DNA and control the expression of
some of their target genes. Macrophages, T and B cells also
express estrogen receptors (ERs) [27]. Indeed, estrogens
regulate the expression of genes that function in macro-
phage activation and cholesterol homeostasis [28].
Another link between the endocrine and immune systems
is that ERs are involved in the development of the thymus,
which is smaller in ER-alpha knockout mice [29]. Interest-
ingly too, expression of ER-alpha is higher in MG than
control thymuses. While that could be an effect of the
autoimmune response, deregulated ER expression could
instead contribute to its induction, maintenance and pro-
gression [30].
We have adopted an independent approach for locating
susceptibility genes that are potentially: a/estrogen
responsive and b/involved in MG. Our method has been
compared with several other computational methods for
prioritizing disease-associated genes, and on the example
of MG we have demonstrated that our results outperform
the others. For 283 candidate genes from the extended
MHC region flanked on both sides, we looked for the
estrogen-response elements (EREs), as well as for other
information that either show that genes are estrogen-
responsive or differentially expressed in the EOMG. We
combined that with other relevant information from the
existing gene annotation and produced a score for each
gene. Eventually, based on that score, we were able to rank
genes for their responsiveness to estrogen and relevance to
MG and among top eight genes we identified HLA-G and
TUBB as new candidates. Our method has a potential to
be generalized for other diseases and other sex hormones,
which is important as many diseases are affected by hor-
mones. This appears to be a pragmatic and inexpensive
strategy to prioritize candidate genes for experimental
investigation of potential involvement in a disease. Con-
sequently, our results open up possibilities for experimen-
talists to focus on a small number of strong gene
candidates for further experimental studies.
Results and discussion
We have developed a computational method to prioritize
genes from a genomic region that are both responsive to
estrogen and involved in a disease (see Materials and
Methods). Our method uses various types of gene infor-
mation (such as responsiveness to estrogen, functional
annotation, etc.) and combines them into a scoring
scheme that allows for genes prioritization. We have dem-
onstrated the method on the example of MG where the
top ranked genes from the prioritized list are enriched
with genes already known to be associated with MG. We
also compared our method with the other available meth-
ods and have shown that it outperforms the others.
(a) Screening for potential estrogen responsiveness
Among the 283 genes in the target genomic HLA-region,
our screening identified 96 genes with predicted EREs. We
found numerous potentially estrogen-responsive HLA-
region genes in the various databases we searched (Addi-
tional file 1, Supplementary Table S1). Notably, they
include HLA-A, -G, -E, and -B, in the class I region, -DRB1,
TAP2 in class II, TNF and LTA (lymphotoxin) – which are
both very close to MYAS 1- and HSPA1A and B, C2 and
CFB complement factors in class III; also TUBB (close to
HLA-E, a microtubule protein that recurs in several inde-
pendent screens).
These genes were then weighted and ranked as described
in (viii, Materials and Methods) (See  Additional file 1,
Supplementary Table S1). Table 1 highlights the 25 ERE-
containing HLA region genes with ranks in the top 50 pri-
oritized genes; the estrogen responsiveness of 6 of these
genes has been verified experimentally (see See Additional
file 1, 'KBERG column' of Supplementary Table S1).
Clearly, therefore, numerous HLA-region genes are estro-
gen-responsive.
Table 1: Potential estrogen-responsive genes in the HLA region
Estrogen-responsiveness identified by All 283 genes Genes in top 50 ranks
our own screening for EREs 96 25
KBERG data base 11 6
ERTargetDB:-
ChIP-on-chip-confirmed 1 0
microarray evidence 4 3
predicted EREs 31 12BMC Genomics 2008, 9:481 http://www.biomedcentral.com/1471-2164/9/481
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Scanning the eVOC ontologies for the 283 HLA-region
genes, we found 157 that are expressed in normal muscle
and 104 in normal thymus (See Additional file 1, Supple-
mentary Table S1). At most, MG only involves minority
components of each of these tissues.
Interestingly, our parallel screening of a list of 59 report-
edly MG-associated genes (See Additional file 1, Supple-
mentary Table S2, see column predicted EREs) detected
EREs in the gene CCR2, IFN-γ, IL-6 and IL-7 but in none
of the other chemokines or cytokines listed, nor in a range
of co-stimulatory molecules including CTLA-4, nor in
PTPN22, a negative signaling molecule with many
autoimmune associations [31]. Since this study focuses
on HLA-region genes, only those of the 59 MG-associated
genes that reside in this region will be analyzed further.
Ten genes out of 59 MG-associated genes are localized
within 10.8 Mbp region we analyzed (See Additional file
1, Supplementary Table S2, highlighted in Yellow). Nine
of these genes were ranked among the top 35 ones (the p-
value of enrichment after Bonferroni correction for multi-
plicity testing is 9.99 × 10-13, with multiplicity correction
factor 283; we used right-hand side exact Fisher's test
based on hypergeometric distribution). The tenth MG-
associated genes, MYAS-1, does not have the exact
genomic coordinates and thus was not suitable for this
analysis, so we did not consider it. The remaining nine
genes, HLA-DRB1, HLA-DPB1, HLA-B, HLA-A, HLA-
DQB1, HLA-DQA1, TNF, HLA-DRA and LTA had rank
positions 3, 5, 9, 16, 20, 24, 27, 30 and 35 respectively.
This suggests that our ranking method seems meaningful
as it can identify 90% of the 10 already known MG-asso-
ciated genes from the considered region among the top
12.5% (35/283) prioritized genes without using any
information that directly links genes to MG (1 MG related
gene in the top 1.06%, 2 MG related genes in the top
1.76%, 3 MG related genes in the top 3.18%, 4 in top
5.65%, 5 in top 7.06%, 6 in top 8.48%, 7 in top 9.54%, 8
in top 10.60% and 9 in top 12.36%).
(b) Cross-checking against genes differentially expressed in 
the MG thymus
We checked two datasets to identify any HLA-region genes
reported to be differentially expressed in the thymus of
female MG patients by [12,13]. The former include HLA-
C, -DQA, -DQB and -DOB, and C2, and the latter TNF and
CFB too; also – in the hyperplastic sub-groups - HLA-B, -
DQA, and -DPA as well as TUBB (Additional file 1, see
details in Supplementary Table S1).
(c) Functional properties of the top 50 prioritized genes
The top 50 genes were next analyzed in more detail
according to their functional properties using GO annota-
tions and the DAVID tool [32]. The functional annotation
and the pathways mapped by top 50 genes are presented
in Additional file 1, Supplementary Table S3.
(d) Comparison with other available methods
We explored possibility to use other reported methods
[33-40] for prioritizing disease-associated genes in the
context of our study. In comparison with the existing
methods that were available for the analysis, our method
was able to identify a greater number of known MG-asso-
ciated genes in the top ranks (Figure 2).
We want to point out that the set of features we have
selected does not determine uniquely Myasthenia Gravis
(MG) associated genes. They, however, indirectly charac-
terize MG and our assumption of relevance of estrogen in
MG. Indeed, all gene prioritizing methods use various sets
of features to indirectly characterize a disease, but none of
these feature sets is sufficient to characterize the disease
completely. For this very reason, it is not useful to search
for the presence of these features for all genes in the
human genome. The rational way to utilize feature infor-
mation is to analyze genes located in the genomic seg-
ments that are shown to contain disease-associated genes
which in our study are MG-associated genes. Such seg-
ments are usually obtained by the linkage analysis. In
such a case, one can make a rational assumption that
genes from these segments are enriched with (in our case)
the MG-associated genes, and thus ranking genes for rele-
vance to MG based on the selected features will be more
efficient and more meaningful. As our results show, the
already known MG-associated genes from the MHC and
surrounding region are located among the top ranked
genes. Moreover, the selection of the MHC and surround-
ing region for the search for MG-associated genes was
guided by the linkage analysis results that suggest that the
epicenter of the early-onset MG is within MHC.
The methodology mentioned above and described in
Materials and Methods has enabled us to identify and pri-
oritize genes likely to be responsive to estrogens and/or
potentially MG-associated. We ranked all known genes
localized on the 10.8 Mbp region of chromosome 6 based
upon predicted EREs, genes' differential expression in MG
thymi (which are likely sites of autoimmunization), their
known responsiveness to estrogen, and their annotated
biological roles. Nine of our 35 top prioritized genes
already feature in a set of 59 known MG-associated genes
(See Additional file 1, Supplementary Table S2); it is
important to note that only 10 of these 59 map within the
10.8 Mbp region we analyzed (See Additional file 1, Sup-
plementary Table S2, highlighted in Yellow); the p-value
of enrichment for known MG-associated genes after Bon-
ferroni correction for multiplicity testing is 9.99 × 10-13
(using a multiplicity correction factor 283, and right-hand
side Fisher's exact test based on hypergeometric distribu-BMC Genomics 2008, 9:481 http://www.biomedcentral.com/1471-2164/9/481
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tion). These nine MG-associated genes include several
that have been strongly implicated since the 1970s –
1990s, notably HLA-DRB1 (rank 3), HLA-B (rank 9), HLA-
DQB1 (rank 20), TNF (rank 24) and HLA-DQA1 (rank
27). This prioritization of several already known MG-
associated genes strongly supports the validity of our
ranking method. Moreover, out of 283 genes, 99 (See
Additional file 1, Supplementary Table S4) are localized
between DR3--B--A1 (genomic location 30,017,016–
32,572,245). Of these 99, 24 are ranked in the top 50; 22
from top 50 reside between DR in class II and HLA-E in
class I (30,565,198 – 32,572,245) where associations
seem strongest in MG (See Additional file 1, Supplemen-
tary Table S5).
In order to show that our selection of weights used for the
five groups of features has no resemblance to the set of
features that produces the best ranking of the MG-associ-
ated genes, we compared the scores and ranks of the MG-
associated genes obtained using weights described in the
Methods section with those obtained using the optimized
weights. To obtain the optimized weights for the five
groups of features we used we systematically changed the
weights within the range from 1 to 10 if the feature was
present, and we set the weight to 0 if it was absent. For
each combination of the weights, we made the ranking of
all genes from the analyzed region. At the end, we selected
the best set of weights (optimized weights) as those that
place all nine known MG-associated genes in the smallest
set of the top ranked ones. We obtained in this way a set
of weights that places all these nine genes in the top 30
ranked genes, as opposed to the top 35 genes that we
obtained by our selection of weights. The comparison
between our originally selected set of weights and the
optimized set are provided in Additional file 1, Supple-
mentary Table S6. This comparison shows that the origi-
nal weights have no resemblance to the optimized ones,
thus proving that we did not specifically tuned original
weights to achieve good ranking of the MG-associated
genes. The problem that appears with the optimized
weights in Additional file 1, Supplementary Table S6 is
that it is difficult to provide suitable interpretation of
these weights.
We attempted to compare several of the reported methods
[33-40] for prioritizing disease-associated genes. Some of
these methods, such as [35,38] are not available as web-
tools, so we were not able to use them. The scope of the
available tools is limited by the data resources and tech-
nologies they use, such as gene ontologies, sequence sim-
Comparison of results obtained using our method, SUSPECTS and PROSPECTR Figure 2
Comparison of results obtained using our method, SUSPECTS and PROSPECTR.
Distribution of known MG associated genes in top ranks obtained using our 
method, SUSPECTS and PROSPECTR
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ilarities, and/or expression. For example, SUSPECTS
require list of genes already known to be involved in the
disease under investigation as a yardstick for comparing
and ranking 'new' genes. Unlike these, our disease gene
prioritizing method: a/does not require prior information
about disease associated genes, and b/is based fully on an
ab initio approach to prioritize candidate disease genes,
which makes it unique and likely applicable to many dis-
eases affected by estrogen or other sex hormones. Only
two (SUSPECTS and PROSPECTR) of the six methods that
have available web-tools for prioritizing disease-associ-
ated genes, produced any results for MG. As can be seen
from Figure 2, our method significantly outperforms both
of these.
The top ranked genes from the considered region include
almost all MG-associated genes from the region. We there-
fore propose that the top 50 genes in the prioritized list
have high probabilities of involvement in MG and also of
estrogen-responsiveness. Indeed, the latter has been
experimentally verified for two of these. HLA-DRB1 (rank
3) is already strongly implicated in MG susceptibility,
though DRB3 may be even more so [41]. The other is
TUBB (rank 8), a microtubule protein; although it may
seem an unlikely candidate, it may warrant further exper-
imental evaluation because axon guidance molecules
have recently proved to be strikingly expressed by GC B-
cells [42]. The top ranked genes are involved in pathways
such as antigen presentation, type I diabetes, cell adhesion
and natural killer cell-mediated pathways (See Additional
file 1, Supplementary Table S3). Approximately 90% of
these genes are involved in the immune response and
~79% are involved in antigen processing and antigen
presentation (See Additional file 1, Supplementary Table
S3); moreover, some of these genes have been implicated
in autoimmune diseases like diabetes mellitus, rheuma-
toid arthritis and MG. The details of few top ranked genes
and their relevance to autoimmune diseases and MG have
been provided in Additional file 2, supplementary mate-
rial M1.
Conclusion
We have developed and successfully implemented a com-
putational method to prioritize genes relevant to MG in a
strongly MG-associating region on chromosome 6. The
methodology we proposed is sound, as demonstrated in
two ways: a/in the top 35 prioritized genes (12.5% of all
analyzed genes) there are 90% (9 out of 10) already
known MG-associated genes from the analyzed genomic
region; b/in comparison with the other available methods
that were available as public tools, our methods performs
considerably better.
We are aware that our study is limited to one particular
region of chromosome 6 and that other genes beyond this
region and on other chromosomes could also be involved
in MG. In addition, estrogen receptors (ER) can also affect
expression of other genes by forming protein-protein
complexes with other transcription factors such as activa-
tor protein-1 (AP-1), Sp1 family, nerve factor-β (NF-β),
which in turn can bind to gene promoters and regulate
their expression, indirectly broadening the range of estro-
gen-responsive genes. Therefore, the EREs, though good
indicators, only partially reflect a gene's potential for
responsiveness to estrogens. Also, our study is exploratory
in nature, providing information that can be helpful for
further follow-up experiments. It could be deepened and
enhanced in many ways, but our primary aim was to pri-
oritize genes based on potential links between MG and
estrogen by a meaningful ranking method, thus opening
avenues for more sophisticated and detailed future stud-
ies. Any data specifically on effects of estrogen in MG
patients would obviously be an invaluable bonus. Hor-
monal influences on expression of susceptibility genes
might well contribute to the gender biases and/or early-
onset in autoimmune diseases. Moreover, we believe that
our method could be adapted to prioritize genes relevant
to other diseases whose susceptibility to hormonal influ-
ences is frequently unjustly neglected. In that case, how-
ever, in our opinion the same weights cannot be used as
the weights are disease specific. However, we think that
the same methodological steps could be applied for dis-
eases other than MG. Determination of the weights could
be objective and data driven, i.e. computational, as we
have used to determine the optimized weights. However,
these may happen to lack suitable interpretation, as we
have experienced exactly in the case of MG.
Methods
Overview of our methodology
(i) We first identified 283 genes in the MHC region, and
(ii) searched computationally for EREs within them [43].
We then checked against two databases of documented
estrogen-responsive genes, namely (iii) KBERG [44] and
(iv) ERTargetDB [45], neither of which is comprehensive.
We further weighted all genes from the analyzed region
according to (v) their expression in the thymus in MG
subgroups; (vi) functional annotation using gene ontol-
ogy (GO), and (vii) eVOC ontologies. Finally, all genes
were ranked (viii) according to a combined overall score:
the top 50 genes were cross-checked (ix) against a set of
reportedly MG-associated genes, and also subjected to GO
analysis for inspection of their main functional categories
[46]. The sensitivity of the method, to identify the known
genes already associated with MG in top ranked positions,
was compared with other available methods (x). It should
be noted that no information about MG is contained in
the GO descriptions we used.BMC Genomics 2008, 9:481 http://www.biomedcentral.com/1471-2164/9/481
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(i) Extraction of 10.8 Mbp region
The extended MHC is a 7.6 Mbp stretch in the 6p22.2-
p21.32 region of chromosome 6 [47]. We also included
upstream and downstream flanking regions, thus extract-
ing a total of 10.8 Mbp from 6p22.3-p21.31 (chromo-
somal localization 23500000–34300000) region using
UCSC Browser http://genome.ucsc.edu based on genome
build hg18 (NCBI build 36.1). Using UCSC browser, we
extracted a list of 805 UCSC IDs that correspond to 283
gene symbols (Supplementary Table S1) for known genes
localized in this region, together with their chromosomal
coordinates. The region, 30,017,016–32,665,603 con-
tains two haplotypes; DR3--B8--A1 and DR15--B7--A3
and former has been associated with EOMG. Further
within this region we have a sub-region extending from
DR- in class II to HLA-E in class I localized between co-
ordinates 30,565,198 – 32,572,245, where associations
seem to be strongest for MG.
(ii) Prediction of Estrogen Response Elements (EREs)
The tool Dragon ERE Finder version 2.0 [43]http://
apps.sanbi.ac.za/ere/index.php was used to predict the
EREs on the whole stretch of 10.8 Mbp. That predicted
470 EREs on both strands in [-3000,+200] promoter
regions at the 5'ends of genes.
(iii) Matching to genes from KBERG database
The genes from the target MHC region were cross-checked
against all the 1516 experimentally confirmed estrogen-
responsive genes in the KBERG database [44]http://
research.i2r.a-star.edu.sg/kberg/.
(iv) Matching to genes in ERTargetDB database
The current version of ERTargetDB [45], http://bioinfor
matics.med.ohio-state.edu/ERTargetDB/ contains:- (a) 40
genes with 48 experimentally verified ERE direct binding
sites and 11 experimentally verified ERE tethering sites;
(b) 42 genes identified via ChIP-on-chip assay for estro-
gen binding (c) 355 genes from gene expression microar-
rays; (d) 2659 computationally predicted genes.
(v) Matching to genes in published microarray datasets derived from 
MG thymi
We next cross-checked the 283 MHC genes against two
datasets of genes differentially expressed in MG thymi;
one [13] was downloaded from Array Express http://
www.ebi.ac.uk/microarray-as/aer/ and another that was
provided as supplementary material with the publication
[12]:-
a) [12] used microarray technology to identify novel mol-
ecules potentially involved in MG pathogenesis. They gen-
erated lists of 157 up-regulated and 227 down-regulated
genes in hyperplastic thymus samples from 45 female MG
patients relative to 33 normal females.
b) [13] performed microarray analyses to identify genes
differentially expressed in thymic samples from females in
different MG subgroups versus non-myasthenic female
controls. Thymic samples were collected from: 1) four
non-MG adult controls (15–19 years old); 2) four (19–25
year old) seropositive MG patients with mild thymic
hyperplasia (with ≤ 2 GCs per section); 3) five (18–22
year old) seropositive MG patients with marked thymic
hyperplasia (≥ 3 GCs per section), 4) three (16–22 years
old) seronegative MG patients (with few GCs if any). This
data was downloaded from Array Express and was ana-
lyzed by centralizing the data at mean = 0 and SD = 1 and
calculating the fold change in expression of genes in dis-
eased states as compared to controls. The top 5% up- and
down-regulated genes were used for further analysis.
(vi) GO analysis
GO [46] term analysis for all the genes in Additional file
1, Supplementary Table S1 was performed using DAVID
(The Database for Annotation, Visualization and Inte-
grated Discovery) version 2.0 [32].
(viii) eVOC ontologies
The eVOC ontologies [48,49] allowed us to assess the dif-
ferential expression of genes in muscle or thymus based
on EST, SAGE and microarray data. A public version of
eVOC is available at http://www.evocontology.org/.
(viii) Gene scoring and ranking
We list information collected for all 283 genes in Addi-
tional file 1, Supplementary Table S1. In total, we used 30
different types of information (features) that characterize
each of the genes in terms of its potential to be controlled
by estrogen as well as its potential to be MG-associated.
However, these features do not imply the same level of
confidence – for example in their estrogen-responsiveness
or involvement in autoimmune responses/diseases. Thus
some genes are already known to be estrogen-responsive
from experimental data (KBERG data); others merely
appear to have an ERE in their extended gene loci. Further-
more, the existing GO annotation implicates many genes
in autoimmune responses, antigen presentation and other
immunological functions. Thus, to integrate all this infor-
mation into a meaningful score we somewhat arbitrary
assigned weights to the available features, with scores
ranging from 0 to 10, based on the following logic. The
scores assigned were: (1) genes in KBERG were assigned
weight 10; (2) all GO categories were assigned weight 8
(these are the functional categories assigned based on
multiple experimental evidences); (3) ERE predictions
(our method and ERTargetDB) and presence in ChIP-on-
CHIP data in ERTargetDB were assigned weight 8 (more
relevant for estrogen response in general and not specific
for MG); (4) microarray evidence was assigned weight 5
(since the genes have been implicated in MG pathogenesisBMC Genomics 2008, 9:481 http://www.biomedcentral.com/1471-2164/9/481
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– though not specifically); and (5) eVOC categories were
assigned a score of 1 (tissue types generally relevant for
MG but not specific enough to provide higher weight). If
the feature considered has not been known to be associ-
ated with the gene, we assigned it the weight of 0.
Finally, we summed all weights assigned to all features for
each of the 283 genes and ranked all genes based on that
score. The higher the score, we expect that the gene is
more likely to be controlled by estrogen and be MG-asso-
ciated (Additional file 1, Supplementary Table S1).
(ix) Matching known genes to those associated with MG
A list of 72 MG-associated genes was retrieved from gene
cards http://www.genecards.org[50], Version 2.37 (Sept
23, 2007). These genes were manually checked for their
relevance to MG and we finally obtained a set of 59 such
genes (Additional file 1, Supplementary Table S2).
(x) Comparison of our method with other published methods
This study is performed based on the new methodology
that we introduced for ranking disease related genes. As
there are several methods/tools developed for this pur-
pose, such as GeneSeeker http://www.cmbi.ru.nl/gene
seeker/[33], Disease Gene Prediction (DGP) http://
cgg.ebi.ac.uk/services/dgp/[34], SUSPECTS http://
www.genetics.med.ed.ac.uk/suspects/ and PROSPECTR
http://www.genetics.med.ed.ac.uk/prospectr/[35,37],
G2D http://www.ogic.ca/projects/g2d_2/[36], POCUS
http://www.hgu.mrc.ac.uk/Users/Colin.Semple/[38] and
methods published by [39,40]. We compared the quality
of the resulting prioritized gene lists for relevance to MG
by our own and these other methods. Only two tools;
SUSPECTS and PROSPECTR were able to produce ranked
lists of candidate genes from the target region and these
results in comparison with ours are given in Figure 2.
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